NCT03091192 2026-04-14Savolitinib vs. Sunitinib in MET-driven PRCC.AstraZenecaPhase 3 Active not recruiting60 enrolled 15 charts
NCT05935748 2025-11-12Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)NiKang Therapeutics, Inc.Phase 2 Terminated18 enrolled